Initial treatment with a low dose of OCS in combination with tezepelumab, an anti-thymic stromal lymphopoietin (TSLP) antibody, resulted in rapid improvement of asthma and CEP without deteriorating LC. The gene discussed is TSLP; the disease is asthma.